Evidence map›Paper›PMID 22852051›Full record

ReviewNutrients2012

Ergogenic effects of β-alanine and carnosine: proposed future research to quantify their efficacy.

John Caruso, Jessica Charles, Kayla Unruh, Rachel Giebel, Lexis Learmonth, William Potter

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05371145 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Carnosine for Peripheral Arterial Disease Patients (Car-PAD)

TypeinterventionalSponsorShahid BabaRan2023 to 2024Enrolled20ConditionsPeripheral Arterial DiseaseArmsCarnosine
NCT06480760 phase1 / phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Effects of Carnosine In Patients With Peripheral Arterial Disease Patients; Randomized Intervention Trial (CIPHER)

TypeinterventionalSponsorShahid BabaRan2025 to 2028Enrolled144ConditionsPeripheral Arterial DiseaseArmsCarnosine
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. The Possible Roles ofCurrent medicinal chemistry · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

John CarusoExercise & Sports Science Program, The University of Tulsa, Tulsa, OK 74104, USA. john-caruso@utulsa.edu
Jessica Charles
Kayla Unruh
Rachel Giebel
Lexis Learmonth
William Potter
University of Tulsa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-alanine is an amino acid that, when combined with histidine, forms the dipeptide carnosine within skeletal muscle. Carnosine and β-alanine each have multiple purposes within the human body; this review focuses on their roles as ergogenic aids to exercise performance and suggests how to best quantify the former's merits as a buffer. Carnosine normally makes a small contribution to a cell's total buffer capacity; yet β-alanine supplementation raises intracellular carnosine concentrations that in turn improve a muscle's ability to buffer protons. Numerous studies assessed the impact of oral β-alanine intake on muscle carnosine levels and exercise performance. β-alanine may best act as an ergogenic aid when metabolic acidosis is the primary factor for compromised exercise performance. Blood lactate kinetics, whereby the concentration of the metabolite is measured as it enters and leaves the vasculature over time, affords the best opportunity to assess the merits of β-alanine supplementation's ergogenic effect. Optimal β-alanine dosages have not been determined for persons of different ages, genders and nutritional/health conditions. Doses as high as 6.4 g day(-1), for ten weeks have been administered to healthy subjects. Paraesthesia is to date the only side effect from oral β-alanine ingestion. The severity and duration of paraesthesia episodes are dose-dependent. It may be unwise for persons with a history of paraesthesia to ingest β-alanine. As for any supplement, caution should be exercised with β-alanine supplementation.

Indexed as

Dietary SupplementsAcidosis, Lacticbeta-AlanineCarnosineExerciseFatigueHumansLactic AcidMuscle, Skeletalbeta-AlanineCarnosineLactic Acidamino acidcarnosinedietary supplementparaesthesia

Identifiers

PMID22852051
PMCPMC3407982
OpenAlexW2074266322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.